Challenges in Regulating Synthetic New Psychoactive Substances: Lessons from Japan's Generic Scheduling against...

Area of Science:

• Pharmacology
• Toxicology
• Public Health Policy

Background:

• Synthetic cannabinoids, such as hexahydrocannabihexol (HHCH), pose emerging health risks, including central nervous system effects like nausea and dizziness.
• Japan's Ministry of Health, Labour and Welfare (MHLW) has historically adapted drug regulations to address novel psychoactive substances (NPS) not covered by existing laws.
• The increasing prevalence of NPS has led to a rise in poisoning cases, prompting regulatory bodies to implement generic scheduling systems.

Purpose of the Study:

• To report on Japan's regulatory action concerning the synthetic cannabinoid hexahydrocannabihexol (HHCH).
• To highlight the public health implications of HHCH and similar emerging psychoactive substances.
• To discuss the challenges and limitations in regulating synthetic cannabinoids.

Main Methods:

• Review of regulatory ordinance announced by Japan's MHLW on December 2, 2023.
• Analysis of the chemical structure and reported adverse effects of HHCH.
• Examination of Japan's evolving drug control strategies and their effectiveness.

Main Results:

• Japan has implemented an ordinance to regulate the possession, consumption, and distribution of HHCH, with exceptions for medical use.
• HHCH's structural similarity to tetrahydrocannabinol is presumed to be the cause of its adverse central nervous system effects.
• Despite previous regulatory efforts, a resurgence in arrests related to designer drugs has been observed, partly due to increased online accessibility.

Conclusions:

• The persistence of HHCH gummy manufacturers indicates limitations in current regulatory frameworks.
• Enhanced health literacy and social responsibility are crucial for mitigating public health risks associated with emerging psychoactive substances.
• Future regulatory frameworks must prioritize public health considerations over economic interests when addressing synthetic cannabinoids.